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Abstract 
Lung cancer is the most common cause of cancer- related death worldwide, causing 
over 1.2 million deaths each year. Non–small-cell lung cancer (NSCLC) consists of a 
group of malignancies that are pathologically and molecularly diverse but that are all 
characterised by a poor prognosis. Survival rates for lung cancer patients have 
improved very slowly and only to a modest degree owing partly to poor funding for 
research into this malignancy and stigma associated with smoking, as well as 
relative chemo-resistance. However, in recent years, NSCLC has become an 
exemplar for precision medicine, mainly following development of drugs targeting the 
receptors of epidermal growth factor and anaplastic lymphoma kinase. While 
epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors are only 
applicable to a minority of patients and benefits are almost invariably short-lived, 
current studies indicate that at least 50% of patients with NSCLC have a targetable 
mutation. With a growing armamentarium of inhibitors against these targets in 
development, there is a hope that a greater proportion of patients will benefit from 
precision medicine and that such benefits will be sustained. However, there remain 
significant challenges in the development of precision medicine in NSCLC. These 
include: identification and validation of new targets; ensuring biopsies are fit for 
purpose; tumour heterogeneity; requirements for serial tumour assessments; and not 
least cost. In this review, we will discuss the current status of precision medicine in 
NSCLC as well as how basic and translational research are paving the way towards 
overcoming the above challenges. In addition, we will pay attention to clinical 
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strategies in respect to liquid biopsies and the potential use of extracellular vesicles 
such as exosomes in cancer therapeutics.  
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Introduction 
Cancer is a devastating group of human diseases that result from uncontrolled 
replication and spread of abnormal cells. There are approximately 14.1 million new 
cancer cases worldwide with 8.1 million of those diagnosed in 2012 expected to die 
from cancer [1, 2].  In the EU approximately 1 359 100 cancer deaths are projected 
in 2015 (592 900 women and 766 200 men), corresponding to a death rate of 138.4 
for men and 83.9 for women per 100 000 people, with a decline since 2009 of 7.5% 
and 6% respectively [3].  
Lung cancer is one of the most common forms of malignancies and the most 
common cause of cancer death worldwide. Lung cancer can be caused by a number 
of factors that include; lifestyle choices including tobacco use, diet and lack of 
exercise; genetics, some infections and environmental contact to certain chemicals 
and radiation. The main causes are smoking, second-hand smoke and alcohol use. 
The NSCLC risk for smokers is increased by 30-fold on a scale depending upon the 
persons clinical story. The second most common cause is exposure to radon, which 
is an invisible radioactive gas produced by the decay of the elements uranium and 
thorium which is present in the soil and rock. Other causes that are not well 
documented for one reason or other, cancers affecting the lung, head and neck 
region such as the oesophagus etc. could be as a result of alcohol use (particularly 
squamous carcinoma) or release of certain types pollution into the environment such 
as from the petrochemical and fertiliser industries due to failings or from improperly 
managed landfill sites.  
Non-Small Cell Lung Cancer (NSCLC) is the most common cause of cancer 
death globally. Although there have been some declines in its incidence in the 
developed world due to changes in smoking habits, these have been more than 
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offset by increases in smoking, and thus NSCLC, in developing countries, most 
notably in China [4]. The majority of patients with NSCLC present with locally 
advanced or metastatic disease that is not amenable to curative treatment. This is 
reflected in the poor prognosis of lung cancer and the death of over 1.2 million 
people worldwide each year [2].  
 
While differences in pathology have long been appreciated, most subtypes of lung 
cancer were until recently lumped into one of two categories for treatment purposes; 
small cell lung cancer, or NSCLC, the latter of which we will discuss here. The gold 
standard chemotherapy for NSCLC is a doublet, including a platinum agent and one 
of several other agents incuding taxanes, gemcitabine and pemetrexed. While 
treatment with chemotherapy has been shown to improve survival in NSCLC, a 
plateau in benefit from chemotherapy appeared to have been achieved around the 
turn of the century, with one landmark trial showing equivalent outcomes between 4 
commonly used regimens [5]. However, since then the importance of histology, and 
indeed molecular subtyping, has emerged. While this has particularly affected 
targeted therapies such as the use of EGFR inhibitors, standard chemotherapy 
agents such as pemetrexed have also been shown to have differential activity in 
different subgroups.  
This has led the evolution of precision medicine in NSCLC. Precision 
medicine as defined by the National Cancer Institute (NCI) is “a form of medicine that 
uses information about a person’s genes, proteins and environment to prevent, 
diagnose and treat disease” [2, 6-9]. In relation to NSCLC, precision medicine has 
thus far mainly been used in guiding treatment options, however there is additionally 
great potential to personalise approaches to diagnosis and prevention in future. 
Challenges and Strategies in NSCLC 
 5 
 
Requirements for precision medicine 
Precision medicine aims to match the right drug with the right patient, maximising 
benefit, minimising toxicity and ultimately reducing cost to the health system by 
reducing use of ineffective treatments. In addition to requiring effective therapies, 
precision medicine is heavily dependent on robust biomarkers that reproducibly 
identify patients likely to respond to treatments. 
 Various factors may be used to stratify treatment, although mostly so far this 
has been through the use of conventional pathology or molecular markers from the 
tumour. Notably the treatment options for only a relatively small proportion of 
patients are truly personalised in NSCLC at present, treatments are often costly, and 
benefits short-lived. There is thus a great need to further develop precision medicine 
in lung cancer, and here we will discuss not only the current status of precision 
medicine in NSCLC in brief, but also potential for the future and how challenges that 
lie ahead may be addressed. 
 
Use of pathology to guide therapy. 
NSCLC is made up of several different histological subtypes, of which 
adenocarcinoma is more frequent now than squamous cell carcinoma, although 
other subtypes exist and adenocarcinoma may be divided into further subtypes [10]. 
In the last decade or so it has become apparent that different subtypes may respond 
differently to treatment. The clinical development of pemetrexed is a prime example 
in which the combination of cisplatin and pemetrexed showed improved outcomes in 
adenocarcinoma but not in squamous cell carcinoma [11]. On the other hand, the 
angiogenesis inhibitor, bevacizumab, is associated with increased toxicity in 
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squamous carcinoma due to increased risks of bleeding [12], which has led to its use 
exclusively in non-squamous carcinomas.  
An early finding during the development of epidermal growth factor receptor (EGFR) 
inhibitors was an increased response rate in adenocarcinomas [13-15]. In addition, 
other characteristics including; never smokers, female, and Asian ancestry were 
additionally found to correlate with response to treatment and were then used to 
stratify treatment in trials [16]. However, these characteristics have subsequently 
been shown to be surrogate markers for EGFR mutations, which are more reliably 
associated with response to EGFR inhibitors. Indeed, as discussed below, this shift 
towards molecular markers has been the driver behind the expansion of precision 
medicine in NSCLC. 
 
Stratifying by molecular characteristics 
Current biomarkers used in cancer diagnosis are either genetic or protein biomarkers 
which can be detected in biofluids such as in the blood or in surgically removed 
tissue. Detection of genetic biomarkers is more reproducible than protein biomarkers 
due to external and internal factors that alter during the progression of cancer [8]. 
Precision medicine is changing how we approach and tackle certain aspects of 
oncology. The course of therapy administered and the response of the patient will 
depend upon understanding individual aspects of molecular carcinogenesis, 
pharmacogenomics and genetic variances [17, 18]. There are a broad range of 
cancer biomarkers that can be used to detect for physiological changes such as 
proteins, sugars, nucleic acids, small metabolites, and cytokinetic and cytogenetic 
parameters, in addition to tumour cells found in the biofluids.   
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There is a growing list of biomarkers that have been developed or are in 
development at the moment for NSCLC patients in the clinical setting. Due to space 
requirements of this review, we will focus on those biomarkers that are in current use 
or emerging into the clinic.  
 
Predictive Cancer Biomarkers 
Cancer biomarkers can give information on the likelihood of responding to certain 
treatments [19] and aid in the decision of therapeutic approach [20]. The main 
predictive biomarkers that are recognised in the clinical setting for the molecular 
diagnostics of cancer are somatic mutations (point mutations and chromosomal 
aberrations), of the following genes: EGFR, EML4-ALK, ROS, RET, MET, HER2, 
KRAS, BRAF, KIT, PDGFRA, and BCR-ABL. Analysis of gene expression or 
methylation is currently a common approach in research than routinely used for 
diagnostics, with the exception in breast cancer assessment of specific genes used 
for predicting treatment response [18]. Nevertheless, there are many NSCLC 
biomarkers that are emerging from current research- EGFR (overexpression), KRAS, 
ROS1, RET, AKL, HER2, MET, ERCC, PIK3CA and BRAF. Some mutations that are 
currently considered to be undrugable, but are important in NSCLC carcinogenesis. 
The p53 tumor suppressor gene is a prime example as it is mutated in more than 
50% NSCLC patients who smoked and used alcohol [21, 22]. Here, we discuss a 
few of the key NSCLC biomarkers, their frequency and associated-therapy (Table 1).  
 
Epidermal Growth Factor Receptor (EGFR) 
The EGFR family of receptor tyrosine kinase, EGFR (ErbB1/HER1), ErbB2 
(HER2/neu), ErbB3 (HER3), and ErbB4 (HER4), are activated by the binding of 
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ligands such as EGF functioning in cell signalling events at the cell surface. The 
classical RTKs are composed of a large extracellular domain, a hydrophobic 
transmembrane domain, and an intracellular domain. The association of the RTKs 
and their respective ligands leads to the homo- or hetero-dimerisation of the 
receptors [23]; consequently, the dimerised RTK can be activated by 
autophosphorylation of free tyrosine amino acids present in the cytoplasmic tail of 
the receptor [24, 25]. The dimerised and activated RTKs are able to recruit other 
signaling molecules prompting many downstream signaling cascades [26-28] that 
regulate cellular proliferation, differentiation, and programmed cell death [24, 29]. 
Subsequently, the numerous signaling transduction pathways activated include the 
MAPK signaling cascade, the phosphoinositide-3- kinase (PI3K) pathway brings 
Akt/PKB to the plasma membrane, and the phospholipase Cγ pathway associates 
directly with EGFR resulting in the protein kinase C (PKC) activation [30]. 
 EGFR activating mutations are considered to instigate cells to grow rapidly. 
Notably, the EGFR gene is mutated in approximately 10% of NSCLC cases overall 
and ~50% of patients who have never smoked [31]. It has been demonstrated the 
somatic EGFR mutations in exons 19 or 21 are linked to tumour sensitivity to 
tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. The survival rate has 
been observed to improve when exon 19 is deleted than compared to exon 21 point 
mutation at position L858R [32]. A Polish cohort study discovered that these 
mutations (exon 19 and exon 21 L858R substitution) in ~12% of cases with 
adenocarcinoma through the study of exon 19 deletion and L858R substitution [33] 
as well as in 13% of patients with the same diagnosis through the study of 29 
mutations in exons 18, 19, 20 and 21 of EGFR gene [18, 34].  
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Regrettably, NSCLC patients acquire resistance to TKI treatment with time. 
Approximately 50% of adenocarcinoma cases have the somatic mutation T790M in 
the kinase domain of EGFR in exon 20 with the exception of mutations that sensitize 
the tumour to TKI treatment [35]. The main mechanism of TKI resistance occurs as a 
result of substitution of a threonine residue for a methionine residue at position 790 
in EGFR which thus enhances adenosine triphosphate (ATP) affinity [36]. 
Furthermore, it is likely that drug resistance in ~20 % of patients are a consequence 
of MET gene amplification which is independent of T790M EGFR mutation. This 
acquired resistance to treatment could be triggered by an activation of the EGFR 
signalling cascade pathways. For progression in EGFR mutation patients under TKI 
(first generation), we observed T790 mutation, cMet, but also transformation in small 
cell lung cancer and nothing else to detect. The clinical development of EGFR 
inhibitors in NSCLC dates back over two decades, and initially involved assessment 
in an unselected population of NSCLC. In the BR.21 trial for example, erlotinib was 
compared to chemotherapy as secondline therapy for NSCLC [14]. In this trial, 
erlotinib improved overall survival from 4.7 to 6.7 months leading to its approval in 
this setting. However, evidence of improved responses in EGFR mutant patients 
emerged. 
 
Current strategies and future developments in anti-EGFR therapies 
The first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) are reversible 
inhibitors such as gefitinib and erlotinib, have already been extensively studied in the 
treatment of advanced NSCLC patients. Tumours harboring activating EGFR 
mutations in particular the deletion in exon 19 (EGFRdel19) and exon 21 L858R 
mutation (EGFRL858R), are more than likely and are predicted to respond to EGFR-
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TKI treatment [37-39]. Numerous phase II and III studies validate the function of first-
line EGFR-TKI treatment in advanced EGFR-mutated lung cancer [16, 40-47]. The 
second-generation of EGFR-TKIs are irreversible inhibitors such as afatinib and 
dacomitinib, with the goal to be more potent in their inhibition of EGFR tyrosine 
kinase and to specifically target other ErbB-family members, including the HER2 
receptor. These receptors can be catalytically activated by a cascade of intracellular 
pathways that play a role in cellular differentiation, migration and proliferation. As yet, 
no HER2 ligand has been identified, even though HER2 shows structural similarity to 
other ERBB receptors. The HER2 receptor is commonly and the preferred dimerising 
partner of EGFR displaying an increased potential compared to EGFR homodimers 
[48]. 
The second-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) are 
irreversible inhibitors such as afatinib and dacomitinib. Afatinib is an inhibitor 
selective against EGFR, HER2, and HER4. A number of reports have demonstrated 
the efficacy of afatinib in first line treatment of advanced EGFR-mutated lung cancer 
[49, 50]. Afatinib has been shown to be active against cancer cells displaying the 
activating EGFR mutations (EGFRL858R and EGFRL858R/T790M) [51, 52]. 
Dacomitinib is a selective inhibitor against EGFR, HER2 and HER4. In vitro studies 
with cell lines and xenograft studies show that dacomitinib is active against EGFR 
mutations and EGFRT790M [53, 54]. 
The third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) are irreversible 
inhibitors such AZD9291, rociletinib, and HM61713.  Both afatinib and dacomitinib 
have activity against both EGFRT790M and wild-type EGFR. However, the third-
generation inhibitors were specifically designed to inhibit only EGFRT790M not wild-
type EGFR [55]. The compound AZD9291 (AstraZeneca; [56]) is structurally different 
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to the first- and second-generation EGFR-TKIs. Early preclinical trials show that 
AZD9291 inhibits the phosphorylation of EGFR in cells with the EGFR mutations 
(EGFRdel19 and EGFRL858R) and EGFRT790M. Recently, AZD9291 entered 
phase I clinical trials in patients with advanced NSCLC with EGFR mutation T790M 
[57]. The results of the study concluded that AZD9291 was highly reactive in lung 
cancer patients with the EGFR T790M mutation [57]. AZD9291 has been shown to 
cause significant and unremitting tumour regression in transgenic mouse models and 
tumour xenograft displaying the EGFR mutation T790M. A number of studies are 
entering clinical trials using large cohorts with other third-generation compounds 
(Table 2). 
An alternative strategy to irreversible and mutation-specific EGFR inhibitors is 
a combination therapy approach. This type of strategy overcomes acquired 
resistance to EGFR inhibition with dual treatment with afatinib and the anti-EGFR 
monoclonal antibody cetuximab. Currently, this therapy combination is in phase IB 
trials advanced NSCLC patients with EGFR-mutation with acquired resistance 
showing promising clinical response irrespective of T790M status [58]. However, 
trials with combination therapy of cetuximab with gefitinib or erlotinib of patients 
displaying acquired resistance to erlotinib showed no response [59]. These results 
implicate that irreversible EGFR inhibition and HER-family inhibition are required for 
the mechanism of action in the case of afatinib and cetruximab combined treatment.  
 
ALK 
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase with unknown 
function normally expressed in the testes, central nervous system, and small 
intestine [60]. The oncogenic activity of ALK in anaplastic large cell lymphoma was 
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reported more than 20 years ago [60]. A recent screen to identify ALK arrangements 
in NSCLC showed that the genes encoding echinoderm microtubule associated 
protein like 4 (EML4) and ALK are found as a fusion oncogene located to 
chromosome 2 [61]. The ALK-EML4 fusion oncogene is important in up to ~7% of 
advanced stage of NSCLC [62]. Likewise, ~6.7% of the Japanese population with 
NSCLC patients were positive for EML4–ALK fusion oncogene [61]. In contrast, 
some other studies demonstrate a variable frequency of EML4–ALK fusion [63-65]. 
Generally, the EML4-ALK oncogene is more frequent in young, male and non-
smoker patients with adenocarcinoma histology [61, 66-68].  
 Fortuitously a drug with activity against the ALK kinase (crizotinib) was 
already available at the time of discovery of the EML4-ALK translocation, allowing 
the rapid instigation of a clinical trial of crizotinib in NSCLC patients with ALK 
rearrangements [62, 69]. The trial demonstrated response rates of approximately 
60% and a 6-month PFS of 72%, with these promising results confirmed in 
subsequent trials including a first line trial in comparison with chemotherapy in which 
crizotinib was superior [62, 70]. A second inhibitor of ALK, ceritinib, has also shown 
activity in ALK rearranged lung cancer, including in patients who had progressed on 
crizotinib [71]. Both agents have now been approved by the FDA and are in wide 
clinical use. Recently, for ALK patients, there is a new drug called Alectinib. This 
drug is for patients who have no response to crizotinib and ceritinib. However, the 
problem for ALK patients is that brain metastasis occurs in these patients with 
treatment (B. Melloni, Personal communication). 
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ROS1 
C-ros (ROS1) is an oncogene encoding for a tyrosine kinase receptor part of the 
insulin receptor family. The rearrangement of ROS1 was first observed in 
glioblastoma [72-74]. Recently, the ROS1 rearrangement was discovered in NSCLC 
cell lines and tumoural tissue [75]. The rearrangement of ROS1 often involved in the 
fusion with other genes such as CCDC6, SDC4, CD74, EZR, KDELR2, LRIG3, 
SLC34A2 and TPM3 [76]. The ROS1 rearrangement in NSCLC occurs in between 
0.7%–1.7% cases [76-78]. The ROS1 translocation is mainly observed in patients 
with adenocarcinoma pathology with a young age and never smoked. Nevertheless, 
ROS1 rearrangement is also demonstrated in patients with squamous pathology 
[77]. The ALK and MET inhibitor crizotinib is active in NSCLC with ROS1-
rearrangement [78]. A recent cohort crizotinib clinical trial (PROFILE 1001) of 
patients with ROS1 translocation observed approximately 72% overall response rate 
(ORR) with 3 patients in remission (median response 17.6 months and median 
progression-free survival (PFS) 19.2 months) [79]. On the other hand, in an 
European study of NSCLC patients positive for the ROS1 gene treated with crizotinib 
(Mean age 50.5 years with ~65% women and ~68% never-smoked), the ORR was 
80%, disease control rate (DCR) at ~87% and PFS was ~9 months. These cohort 
studies highlight that the patients’ response to crizotinib vary according to the 
geographical location and that other factors may contribute to the progression of 
NSCLC in patients harbouring the ROS1 rearrangement. There are a number of 
drugs in development for lung cancer patients positive for ROS1 including AP26113, 
ceritinib, foretinib, PF-06463922 and inhibitors against HSP90 [80]. 
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RET 
The receptor tyrosine kinase, RET (rearranged during transfection) was an 
oncogene originally identified in thyroid cancer that is epigenetically controlled 
through translocations and activating mutations [24, 81]. RET translocations can be 
detected in about 1-2% of NSCLC patients with adenocarcinoma histology and 
poorly differentiated tumours who are often young and never smoked [82].  
 
KRAS 
KRAS was the first oncogene to be characterised and is part of the RAS oncogene 
family along with HRAS and NRAS [83]. The KRAS mutations in lung cancer are 
found in approximately ~25% of adenocarcinoma and ~4% of squamous cell 
carcinoma [84]. The KRAS gene is more common in smokers and infrequently 
detected in East Asian patient cohorts [85, 86]. KRAS mutations are normally 
present along with other types of oncogenic mutations in EGFR, BRAF, and HER2 or 
rearrangements in ALK and ROS1 [87]. The KRAS mutations are more common in 
NSCLC than HRAS and NRAS [84]. The predictive role and prognostic value of 
KRAS mutations remains controversial. For early stages of lung cancer, KRAS 
mutations have no prognostic or predictive value for chemotherapy treatment. At an 
early stage of lung cancer, KRAS mutations have no prognostic relevance or 
predictive to be used in adjuvant chemotherapy [88]. Conversely, in a NSCLC meta-
analysis data review of the literature revealed negative correlation of the prognostic 
impact of RAS mutations mainly in adenocarcinoma cases [89]. While the KRAS 
mutations in patients with a form of metastatic NSCLC, these patients showed no 
response to chemotherapy [90, 91]. Nevertheless, the response to EGFR TKIs is 
negatively predicted through KRAS mutations [35, 92, 93]. 
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ERCC1 
The ERCC1/xeroderma pigmentosum, complementation group F (XPF) is found as a 
heterodimer and is a member of the XPF/MUS81 family. The ERCC1 gene is located 
on chromosome 19 and is present as four isoforms. It plays a major role in DNA 
repair pathways such as in UV-induced lesions and intra- or interstrand cross-links. 
A number of studies suggest that ERCC1 at the level of DNA, mRNA or protein, 
could be a prognostic or predictive biomarker for NSCLC patients treated with 
platinum doublets [94-99]. A well-established mechanism of cisplatin-resistance is 
related to ERCC1 overexpression. The levels of ERCC1 can also predict both patient 
survival and response to cisplatin therapy after resection in NSCLC patients [100, 
101]. Surgical resection of NSCLC tumours receiving no additional treatment display 
an improved survival with ERCC1-positive as opposed to ERCC1-negative. Hence, 
the presence of the ERCC1 marker provides favourable prognosis and there is no 
benefit from adjuvant platinum chemotherapy. Though, the absence of ERCC1 from 
the tumour in NSCLC patients without treatment gives a poor prognosis and these 
patients would benefit from adjuvant cisplatin-based chemotherapy. Therefore, high 
levels of ERCC1 is a negative predictive marker, signifying to how well the patient 
will respond to certain types of treatment [97, 102].  
 
Other biomarkers 
c-MET is a receptor tyrosine kinase, is a receptor to hepatocyte growth factor which 
activates many downstream signalling pathways. This receptor has a global cellular 
function in proliferation, motility, migration and invasion. The c-MET receptor has a 
normal physiological control of tissue homeostasis but in cancer it becomes 
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deregulated as result of epigenetic and proteic changes such as mutations and 
amplification, or protein overexpression respectively. Interestingly, around 20% of 
cases with MET gene amplification that is independent of T790M EGFR mutation 
could be a potential cause of drug resistance. The deregulation of cMET receptor 
could be a source of resistance to treatment through activation of the ERBB 
signalling pathway. Some studies have demonstrated that ERBB signalling requires 
MET activity using the promising small molecule multikinase inhibitor (XL880) that is 
highly specific of MET or RNA interference to block MET expression [103]. 
There is a growing trend across several institutions and groups that has instigated 
genomic profiling contributes to the therapeutic direction for patients diagnosed with 
NSCLC [87, 104, 105]. A large cohort US collaborative study called ‘The Lung 
Cancer Mutation Consortium’ involving 14 academic institutions (ClinicalTrials.gov id: 
NCT01014286) was recently initiated with the view to genotype ten mutations 
associated to adenocarcinoma histology. This study uses the multiplex PCR 
‘SNapShot’ technology that can identify potential molecular targets in lung cancer 
from genomic DNA derived from small amounts of formalin-fixed paraffin-embedded 
tumour samples. In addition, along with the analysis for ALK rearrangement and 
MET amplification using the FDA-approved fluorescent in-situ hybridization [106]. 
This assay is widely used within the cancer research community and is showing 
promise in the clinical setting [107]. This study reveals an actionable driven mutation 
in 54% of tumours analysed with 22% KRAS mutation, 17% EGFR mutation and 7% 
EML4-ALK rearrangement [106].  
 These biomarkers can be used before and during cancer treatment 
management for the risk assessment, diagnosis, prognosis, and for the prediction of 
outcome such toxicity and recurrence. 
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Identifying biomarkers for response to immune therapy 
Recent trial results have confirmed the emergence of an exciting new class of 
therapy for lung cancer, the immune checkpoint inhibitors [108, 109]. These agents 
target inhibitory receptors on cancer or immune cells which would normally have an 
immunosuppressive effect, with the checkpoint inhibitors thereby ‘releasing the 
breaks’ on the immune system and allowing it to recognise and eliminate malignant 
cells [110]. The most exciting agents at present target the interaction of programmed 
cell death protein 1 (PD-1) (lymphocytes) with its ligand programmed death-ligand 1 
(PD-L1) (cancer cells). Although relatively early, the data support activity for anti-PD-
1 and anti-PD-L1 agents in both adenocarcinoma and squamous carcinoma. Notably 
only a relatively small proportion of patients appear to benefit significantly, however 
these may have prolonged responses to treatment. Therefore, there is a clear need 
to identify markers that predict response. Prime among candidate biomarkers is PD-
L1 expression on cancer cells, with the seminal Keynote-001 study of 
pembrolizumab in NSCLC showing higher response rates and improved PFS in 
patients with high PD-L1 expression [109]. However, on the other hand, in the 
randomised phase III study of nivolumab there was no correlation between either 
PFS and OS and PD-L1 expression [108]. The reason for this disparity is unclear, 
although a recent analysis of multiple studies suggests that PD-L1 expression is 
predictive for response to both nivolumab and pembrolizumab. It is likely that the 
performance of different assays also contributes to differences in apparent 
correlation. That said, correlation between PD-L1 expression and response is 
imperfect, with responses likely also occurring in a proportion of PD-L1 low. In view 
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of this, there is active investigation into alternative biomarkers, with the main 
examples being mutational burden and gamma interferon signatures.  
 
Liquid biopsies- the future? 
A liquid biopsy is a biomarker isolated easily from body fluids such as blood, saliva, 
urine, ascites, and pleural effusion. Liquid biopsy was originally used to describe 
circulating tumour cells (CTCs) [111]. Presently, circulating tumour DNA (ctDNA) and 
exosomes are also used [112-114] (Figure 1). Liquid biopsy is an emerging field in 
oncology that could be useful in predicting cancer progression and determining the 
route of therapy to utilise in the clinic. They could be used at different stages 
including for early diagnosis; prediction of metastasis; monitoring efficacy of 
treatment; identifying potential new targets and mechanisms of resistance; and 
following metastasis in the patient [111].  In fact, analysis of CTCs, ctDNA and 
exosomes will provide a clearer picture concerning the information of both the 
epigenetic and proteomic profile than a tissue biopsy. Furthermore, the liquid biopsy 
is a non-invasive procedure and can be performed on most body fluids. 
CTCs are derived from the primary tumour site by cell detachment and migration to 
distal secondary sites accessed through the lymphatic and blood system. These 
cells can be found in the blood of patients with solid tumours and their presence is 
linked to a poor outcome in metastatic cancer for lung and other solid tumours [115-
117]. The analysis of CTCs can be used to measure the progression of the cancer 
and the metastatic process. A majority of studies have concentrated their efforts 
towards the epigenetic analysis such as circulating miRNAs, mRNA and mainly cell 
free DNA (cfDNA). This analysis of miRNA has provided a clear signature profile, 
which can determine the presence of the cancer [118]. A number of studies are 
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emerging of novel biomarkers used to identify cancer using the non-coding RNA 
(ncRNA) and the long-non-coding RNA (IncRNA) [119]. cfDNA is released from both 
healthy and cancer cells but in disease the levels increase with progression of 
cancer [120]. The analysis of ctDNA from a liquid biopsy can provide both 
information concerning the emergence of mutations acquired during treatment and 
be a non-invasive method to monitor outcome of treatment [114]. 
Cancer changes according to progression and treatment, which is often 
molecularly not stable. In the case of lung cancer, the most common EGFR 
mutations or ALK rearrangements, patients have benefits with TKI treatment such as 
afatinib, gefinib, elotinib, crizotinib, and ceritinib [126, 127]. Unfortunately, these 
benefits to treatment are short-lived due to acquired resistance to treatment [128, 
129]. Liquid biopsy provides information from a simple and non-invasive blood test. 
In addition, tumour dormancy can be studied through ctDNA analysis. A number of 
studies have demonstrated that T790M EGFR mutations can be detected in the 
blood sometime before the disease can be found with conventional methods such as 
radiological [79, 130, 131]. However, at the present liquid biopsy is a challenge for 
the analysis of cancer originating from the nervous system, the lung and the bone. It 
is also important to provide a new biopsy at the time of progression. 
Extracellular vesicles (EV) ranging in size from 30 to 1000 nm such as 
exosomes, ectosomes, microvesicles, oncosomes, and shedding bodies i.e. 
apoptotic bodies [121]. Exosomes (ranging in size 30 to 100 nm) are the smallest 
class of EVs found in most body fluids, are derived by an inward budding event of 
the late endosome or multivesicular body [122, 123].  Exosomes contain a plethora 
of signalling proteins, miRNA, mRNA and lipids [124, 125]. They are released from 
both healthy and cancer cells but their numbers increase exponentially with 
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progression of cancer. Exosomes are believed to provide the first communication 
network between tumour cells, its microenvironment and at distal sites transported 
by the blood circulation. In NSCLC patients, they can be detected in many body 
fluids including the plasma and bronchoalveolar lavage [126]. Their function may 
change during the progression of cancer in the earlier stages they could provide a 
means to evade immune detection, providing nutrient support from the 
microenvironment through release of growth factors and a communication system at 
later stages crucial for assisting the metastatic process [127].  These changes could 
be undetectable in the tumour-alone with current procedures whilst in EVs could 
provide a clearer picture for progression and outcome [128]. Exosomes also contain 
double-stranded DNA (dsDNA or exoDNA), which also could be used in genetic 
profiling to identify potential cancer biomarkers [129]. Numerous researchers have 
systematically investigated the content of EVs using proteomic approaches and 
miRNA microarrays. Molecules specific to disease identified in EVs are now being 
developed as novel diagnostic biomarkers and therapeutic targets for a range of 
human disorders including several lung diseases. 
In the last 10 years, EVs and exosomes have been shown to be enriched and 
provide a protective environment for mRNA and miRNAs [124]. miRNAs are small 
non-coding RNAs with many functions and believed to control various genes by 
weakly binding to the 3’UTR of their target mRNA causing the deregulation of its 
target genes [130, 131]. The expression of several genes in neighbouring cells and 
within the microenvironment can be influenced by a single miRNA. The miRNAs 
have the power to effect both the secretion at their primary site and at distant sites 
through the circulation [132]. In different cancers, circulatory miRNAs are being 
extensively investigated as potential cancer biomarkers [133]. It is well-established 
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that exosomal miRNAs control intercellular communication [134]. In 2007, Valadi and 
colleagues showed for the first time that miRNA could be transported to 
neighbouring cells via exosomes which gave birth to the idea of genetic intercellular 
communication [124]. This study demonstrated that mouse exosomal RNA could be 
transferred and expressed in human mast cells. In later studies, some groups 
showed that the activity of miRNA could be regulated by exosomal transport [135]. 
Exosomes provide a protective cushion encapsulating miRNA such as in extreme 
environments (fecal matter) especially observed in the case of colon cancer [136]. It 
is suggested that mesenchymal stem cells (MSC) secrete mainly pre-miRNAs as 
opposed to mature miRNAs [137]. In MSC, RNA silencing was undetected indicating 
that pre-miRNAs in MSC exosomes have the potential to be active in the 
neighbouring cells. Nevertheless, both pre- and mature miRNAs have been isolated 
from different types of tumour cells. In a Drosophilia model, exosomes have been 
shown to induce miRNA splicing [138]. In later studies, a number of groups have 
proposed to use exosomal miRNAs for diagnostic and prognostic purposes for 
several cancers such as breast [139], lung [140], colon [141], esophageal squamous 
cell carcinoma [142], glioblastoma [143], kidney [144], leukemia [145], ovarian [146], 
prostate [147, 148], and for other cancers [149]. 
A number of studies have shown deregulation of exosomal-miRNA levels as a 
potential biomarker for cancer [150]. For example, exosomal levels of miR-141 and 
miR-375 can be used to predict metastasis or the recurrence of disease in prostate 
cancer [151]. There are diverse changes to the exosomal miRNA profiles of ovarian 
cancer compared to benign ovarian tumours. In addition, exosomal miRNA in normal 
controls is absent and can be used to determine healthy patients from patients with 
disease [152]. Likewise, in lung cancer, there are significant differences in the total 
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exosomal RNA levels of patients versus healthy control [153]. Whilst at the same 
time, in lung cancer patients there was a similarity between exosomal miRNA found 
in the circulation and the miRNA profiles observed in the tumour [140]. In particular, 
levels of specific exosomal miRNAs (miR-17-3p, miR-21, miR-106a, miR- 146, miR-
155, miR-191, miR-192, miR-203, miR-205, miR-210, miR- 212, miR-214) are 
elevated in lung cancer [140]. In lung adenocarcinoma patients, the circulating 
exosomes were significantly higher compared to control [140]. This study and in 
several other studies, the identity of the purified exosomes is validated by electron 
microscopy and Western blot with exosome markers. Hence, relying solely on these 
techniques to identify exosome populations is invalid and highlights the need to 
develop new technologies to detect EVs. In fact, it’s necessary to analyse the whole 
population of EVs to be certain not to exclude certain populations. The sizes of 
vesicles can be altered through modification of the lipid content and the exosome 
formation processes occurring at the multivesicular body [125]. In patients with lung 
adenocarcinoma, circulating exosomes were significantly higher than in control 
group [83]. Ultimately, serum harvested exosomal miR-1246 was elevated in 
esophageal squamous cell carcinoma (ESCC) patients, and is considered to be a 
strong impartial risk factor for poor survival [154]. Together, these studies confirm 
that the analysis of circulating exosomal miRNAs would be an extremely useful tool 
in cancer diagnostics. 
Exosomes contain a plethora of more than 400 proteins; most of these 
proteins have diverse biological functions within the cell and microenvironment. 
Some of these proteins are involved in cellular metabolism or have a structural 
function and are associated to the cytoskeleton although, most importantly 
exosomes contain proteins that are potentially involved in cell signaling pathways. 
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The impact of these facilitators on the neighbouring or distant cell signaling pathways 
essentially remains to be elucidated [155]. The EGFR signaling cascade regulates 
several pathways involved in cell survival, adhesion, migration, differentiation, and 
proliferation [156]. The EGFR signaling pathway is linked to 3 main mitogen-
activated protein kinase (MAPK)-pathways and the phosphoinositide 3-kinase 
(PI3K)/AKT survival pathway. The MAPK pathway is composed of the ERK1/2 part, 
the p38 MAPK part, and the JNK part. Microenvironment communication through 
neurotrophin signalling could lead to the progression of cancer [157-159] while an 
imbalance in expression of neurotrophin receptors such as sortilin is strongly linked 
to different types of cancer [160-163]. In a previous study, we discovered that the 
EGFR signalling pathways are induced between 3 to 50-fold in endothelial cells 
exposed to NSCLC exosomes enriched for the neurotensin receptor 3, also known 
as sortilin [125]. 
A number of proteomic studies use cell culture media and biofluids to analyse 
tumour-derived EVs [164]. Proteomic EV analysis of malignant pleural effusion from 
NSCLC patients reveals that the EVs contain over 900 proteins including EGFR, 
RAB family proteins, K-RAS, carcinoembryonic antigen-related cell adhesion 
molecule 6 (CEACAM6), basigin (CD147, EMMPRIN), claudin-1 and claudin-3 [165]. 
A number of potential biomarkers found in exosomes have been reported such as 
leucine-rich α2-glycoprotein (LRG1), EGFR, CD91, CD317, and antigen A-kinase 
anchor protein 4 (AKAP4) [165-168]. In a recent study, NSCLC patients were 
distinguished from control subjects via differential display of 30 EV protein 
biomarkers from plasma using an ELISA-based method [169]. We have reported that 
a specific marker of NSCLC exosomes, sortilin forms a trimeric complex with two 
tyrosine kinase receptors TrkB (also known as NTRK2) and EGFR called the TES 
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complex [125]. Altogether, these data indicate the need to identify specific 
biomarkers and to develop specific EV technology for lung cancer. This will allow 
improvements to be made to the sensitivity of early diagnosis and to assess the 
progression of cancer, which is necessary to enhance patient outcome and survival. 
EVs derived from the tumour site are believed to act as biological heralds in 
human disease such as in cancer and are thought to transfer the tumoural growth 
signals. Presently, it is implicated that the release of EVs-derived from the tumour 
site could symbolize a prospective target for cancer therapy [170]. A number of 
studies have reported that by perturbing EV release from cells through specifically 
targeting Neutral sphingomyelinase 2 (nSMase2) may decrease tumoural growth 
and metastasis at distant site [171, 172]. In NSCLC cells, other factors regulate EV 
secretion such as Rab27A [125] and p53 [173]. Though inhibiting these factors has 
been demonstrated to be effective against cancer, it will be necessary to study the 
molecular mechanisms of how specifically inhibiting EVs-derived from the tumour 
site are released from lung cancer cells. Moreover, the elimination of tumoural EVs 
from the circulation could be a possible therapeutic approach. This approach has 
recently been suggested by extracorporeal hemofiltration of a specific population of 
circulating of metastatic cancer patients [174]. 
While the function of proteins identified in the cargo of EV-derived from the 
tumour remains to be elucidated in most cases, those tumoural EV-derived proteins 
might stimulate the pathological-related mechanisms associated with disease. 
Likewise, EV-derived proteins could be used as biomarkers in therapy and thus 
could predict the response to treatment in NSCLC. In recent NSCLC proteome 
studies, EVs phospholipid content were modified significantly with gefitinib resistance 
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[175, 176]. This study suggests that EVs phospholipid metabolism could signify a 
tumoural phenotype and is associated to gefitinib resistance. In addition, cisplatin 
treatment of A549 cells sufficiently reduces the sensitivity of non-exposed A549 cells 
to cisplatin [177]. While the actual mechanism of EV-mediated cisplatin resistance 
remains to be decided. This study implicates that by modifying EV formation and 
release could be a future strategy for lung cancer therapeutics. 
 
Conclusions 
Precision medicine has already made a significant impact in NSCLC, and its remit is 
likely to grow. Through an improved understanding of its biology we have an 
unprecedented opportunity to develop the field, and overcome the many challenges 
that are outlined above. The key for future treatment is early detection of the cancer, 
which would improve the chance of survival and reduce mortality as a result of 
cancer. Many current efforts are devoted to developing new technologies steered 
towards early diagnosis. Liquid biopsies have the potential to overcome many of the 
shortcomings of current clinical management of NSCLC. 
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Figure legends 
 
Figure 1 
Liquid biopsy approaches and their potential use in lung cancer. CTCs can be found 
in the blood circulation and are generated by detaching from the tumour mass. The 
ctDNA originates from the tumour during necrotic events while cfDNA can be 
released from both healthy and tumour cells. Exosomes are actively released from 
most cell types and their numbers increase in cancer. 
 
Table 1 
A comparison of key NSCLC biomarkers, their frequency and associated-therapy. 
 
Table 2 
A comparison of first-, second- and third-generation TKIs against ErbB family 
members and their half maximal inhibitory concentration (IC50). 
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Figure 1 
Table 1 
 
Biomarker  Aberration  Frequency of 
aberration (%) 
Therapy 
EGFR  Mutation or 
amplification 
10‐25  Erlotinib, gefitinib, 
cetuximab 
EML/ALK  Fusion  5‐13  Crizotinib 
ROS  Fusion  2  Crizotinib 
RET  Mutation or 
translocation 
1  Vandetanib, 
Sorafenib, and 
Sunitinib (clinical 
trials) 
KRAS  Mutation leading to 
activation 
15‐25  Selumetinib and 
docetaxel combined 
cMET  Mutation or 
amplification 
2‐4  Crizotinib 
 
 
 
 
 
   
  
Table 2 
 
Generation  Inhibitor  Type of therapy  Target (IC50, nM) 
First  Gefitinib 
(AstraZeneca and Teva) 
 
Reversible TKI  EGFR (3) 
HER2 (1830) 
 
  Erlotinib 
(Genentech, OSI 
Pharmaceuticals and 
Roche). 
 
Reversible TKI  EGFR (0.5) 
HER2 (512) 
 
  Icotinib 
(Beta Pharma) 
 
Reversible TKI  EGFR (5) 
Second  Canertinib (CI‐1033) 
(Selleck) 
Irreversible TKI  EGFR (0.8) 
HER2 (19) 
HER4 (7) 
 
  Neratinib (HKI‐272) 
(Puma Biotechnology) 
Irreversible TKI  EGFR (92) 
HER2 (59) 
 
  Dacomitinib 
(PF‐00299804) 
(Pfizer) 
Irreversible TKI  EGFR (6) 
HER2 (46) 
HER4 (74) 
 
  Afatinib (BIBW 2992) 
(Boehringer Ingelheim) 
Irreversible TKI 
 
EGFR (0.5) 
HER2 (14) 
 
Third  AZD9291 (AstraZeneca)  Irreversible TKI 
 
EGFR mutation 
(100) 
  Rociletinib (Clovis)  Irreversible TKI  EGFR mutation 
(21) 
 
  WZ4002 (Selleck)  Irreversible TKI  EGFR (8) 
 
  HM61713 (Hanmi) 
 
Irreversible TKI  EGFR mutation 
(10) 
 
 
 
